Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IBO vs ANRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IBO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–3 Matrix Metrics)

IBO Overall Winner 6-Pillar Tally: IBO 4 – 1 ANRO (1 Tie) Matrix Metrics: IBO 6 – 3 ANRO

As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Alto Neuroscience Inc. (ANRO) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBO carries a Unified Composite Score of 36.8/100 (SELL) at $4.96 (N/M Forward P/E, -12621.0% operating margin), whereas ANRO carries 29.3/100 (SELL) at $27.59 (N/M Forward P/E, 0.0% operating margin).

  • Defensive Composite Rating Caution: Although IBO compares more favorably head-to-head, both IBO (36.8/100 SELL) and ANRO (29.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IBO vs ANRO
IBO NYSE American Head-to-Head Winner
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.96
-3.5% 1D
Market Cap $41.2M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol -6.75β · 120% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (71.0% over 20 days), RSI 62
RSI-14: 62.4 · SMA20: $4.12 · SMA50: $3.52
ANRO NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$27.59
-6.62% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.95β · 89% Vol
Unified Composite Score
29.3 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 56.6 · SMA20: $24.87 · SMA50: $26.21

6-Pillar Scorecard Institutional Category Breakdown (IBO 4 – 1 ANRO)

Columns: Metric · IBO · ANRO
1. Valuation Multiples IBO
Forward P/E N/M N/M
Trailing P/E 0.4x N/M
PEG Ratio N/M N/M
EV / Revenue 18.2x N/M
2. Growth & Scale IBO
Revenue Growth (YoY) +16.7% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.3M N/A
Market Cap $41.2M $1.2B
3. Profitability & Quality IBO
Gross Margin N/A N/A
Operating Margin -12621.0% 0.0%
Net Profit Margin 4247.4% 0.0%
Return on Equity (ROE) 71.2% -46.7%
4. Balance Sheet & Cash Flow IBO
Cash Generation (TTM) -$99M -$80M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.18 Book/Sh · 71.2% ROE $301M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANRO
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 79.4% (8th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IBO (6) vs ANRO (3)
Institutional Metric IBO ANRO Criterion Row Edge
Market Capitalization
Scale
$41.2M $1.2B Larger Scale ANRO
Trailing P/E Ratio
Valuation
0.4x N/M Lower Multiple IBO
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+16.7% +0.0% Higher Growth IBO
Operating Margin (TTM)
Profitability
-12621.0% 0.0% Higher Margin ANRO
Net Profit Margin
Profitability
4247.4% 0.0% Higher Margin IBO
Return on Equity (ROE)
Capital Efficiency
71.2% -46.7% Higher ROE IBO
52-Week Range Position
Momentum
68% ($0–$7) 63% ($11–$37) Stronger Trend IBO
Beta / 30D Volatility
Risk Regime
-6.75β · 120% Vol 1.95β · 89% Vol Lower Realized Risk ANRO
Unified Institutional Score
Composite Signal
36.8 / 100 (SELL) 29.3 / 100 (SELL) Higher Composite IBO
Trailing 12M Revenue (USD)
Operating Scale
$2.3M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$99M ($1.18 Book/Sh · 71.2% ROE) -$80M ($301M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IBO +59.34 pp
IBO: +85.07% · ANRO: +25.73%
3M Horizon IBO +974.5 pp
IBO: +955.32% · ANRO: -19.18%
6M Horizon IBO +794.88 pp
IBO: +821.42% · ANRO: +26.54%
1Y Horizon IBO +729.51 pp
IBO: +872.55% · ANRO: +143.04%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IBO vs ANRO. Trailing 12-month operating profitability (IBO -12621.0% vs ANRO 0.0%) and valuation multiples (IBO N/M vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IBO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.3M
Gross MarginN/A
Op. Margin-12621.0%
ROE / Fwd P/E71.2% · N/M
ANRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-46.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IBO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IBO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANRO CONSOLIDATION
57d in phase · OBV ACCUMULATION
Current IV 79.4%
IV Percentile 8th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ANRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IBO Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $41.2M market capitalization and -12621.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IBO vs ANRO Key Questions & Quantitative Answers

As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Alto Neuroscience Inc. (ANRO) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBO carries a Unified Composite Score of 36.8/100 (SELL) at $4.96 (N/M Forward P/E, -12621.0% operating margin), whereas ANRO carries 29.3/100 (SELL) at $27.59 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although IBO compares more favorably head-to-head, both IBO (36.8/100 SELL) and ANRO (29.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

IBO leads the Growth & Scale pillar: IBO posts +16.7% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (N/A gross margin, -12621.0% operating margin), compared with ANRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, IBO generates $2.3M in USD-normalized revenue versus N/A for ANRO. In operating R&D and SG&A reinvestment, IBO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANRO.

IBO screens cheaper on headline valuation multiples. IBO trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and 18.2x EV/Revenue (unreported FCF margin), whereas ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IBO (71.2% ROE) versus ANRO (-46.7% ROE) capital efficiency.

In options market volatility and institutional positioning, IBO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-6.75β · 120% Vol realized risk). By comparison, ANRO carries 79.4% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.95β · 89% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.